[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Kura Oncology (KURA)

Kura Oncology (KURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,126,246
  • Shares Outstanding, K 88,961
  • Annual Sales, $ 67,480 K
  • Annual Income, $ -278,670 K
  • EBIT $ -318 M
  • EBITDA $ -326 M
  • 60-Month Beta 0.38
  • Price/Sales 17.38
  • Price/Cash Flow N/A
  • Price/Book 24.16

Options Overview Details

View History
  • Implied Volatility 76.18% (-18.24%)
  • Historical Volatility 65.52%
  • IV Percentile 8%
  • IV Rank 7.76%
  • IV High 434.09% on 02/04/26
  • IV Low 46.05% on 05/19/26
  • Expected Move (DTE 20) 0.47 (3.69%)
  • Put/Call Vol Ratio 1.36
  • Today's Volume 2,373
  • Volume Avg (30-Day) 2,078
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 13,542
  • Open Int (30-Day) 9,495
  • Expected Range 12.19 to 13.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.84
  • Number of Estimates 5
  • High Estimate $-0.74
  • Low Estimate $-0.99
  • Prior Year $-0.85
  • Growth Rate Est. (year over year) +1.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.82 +43.54%
on 08/03/26
13.90 -8.92%
on 08/25/26
+3.35 (+35.98%)
since 07/28/26
3-Month
8.39 +50.89%
on 06/08/26
13.90 -8.92%
on 08/25/26
+2.69 (+26.98%)
since 05/28/26
52-Week
7.36 +72.07%
on 02/05/26
13.90 -8.92%
on 08/25/26
+4.59 (+56.88%)
since 08/28/25

Most Recent Stories

More News
The $1.24 Billion Reason Why Kura Oncology Stock Is Up Today

Kura Oncology stock rallies as the CEO revealed another $1.24 million purchase of company shares. Wall Street continues to see massive further upside in KURA shares.

KURA : 12.66 (-3.95%)
Kura Oncology: Q2 Earnings Snapshot

Kura Oncology: Q2 Earnings Snapshot

KURA : 12.66 (-3.95%)
Kura Oncology Reports Second Quarter 2026 Financial Results

– KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q – – KOMZIFTI ® achieved majority share...

KURA : 12.66 (-3.95%)
Kura Oncology Reports Second Quarter 2026 Financial Results

– KOMZIFTI® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q –

KURA : 12.66 (-3.95%)
Kura Oncology Reports Tomorrow With Analysts Already Lowering the Bar by Double Digits

Barchart Research What to Expect from KURA Earnings KURA Generated August 11, 2026 Current Price $9.93 EPS Estimate $$-0.89 Consensus Rating Strong Buy Average Move 2.22% Kura Oncology Reports Tomorrow...

KURA : 12.66 (-3.95%)
Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity

– Publication details the discovery and preclinical characterization of ziftomenib, including its potency, selectivity, and mechanism of action – – Findings demonstrate differentiated menin...

KURA : 12.66 (-3.95%)
Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity

– Publication details the discovery and preclinical characterization of ziftomenib, including its potency, selectivity, and mechanism of action – –...

KURA : 12.66 (-3.95%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 12.66 (-3.95%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the...

KURA : 12.66 (-3.95%)
Kura Oncology Reports Tomorrow With Analysts Finally Aligned on Direction, If Not Magnitude

Barchart Research What to Expect from KURA Earnings KURA Generated August 5, 2026 Current Price $9.20 EPS Estimate $$-0.89 Consensus Rating Strong Buy Average Move 2.22% Kura Oncology Reports Tomorrow...

KURA : 12.66 (-3.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL,...

See More

Key Turning Points

3rd Resistance Point 13.58
2nd Resistance Point 13.37
1st Resistance Point 13.02
Last Price 12.66
1st Support Level 12.46
2nd Support Level 12.25
3rd Support Level 11.90

See More

52-Week High 13.90
Last Price 12.66
Fibonacci 61.8% 11.40
Fibonacci 50% 10.63
Fibonacci 38.2% 9.86
52-Week Low 7.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.